January 28, 2013
Doubters feel the fury of a triumphant Furiex Pharmaceuticals, as shares popped by 66% in a single day. In the following video, Motley Fool health-care analyst David Williamson explains how approval of a trio of diabetes drugs for Takeda was responsible for this pop and takes a closer look at Furiex as an investment.
For nearly 100 years, Merck's cutting-edge research has led to a number of medical breakthroughs. Today, however, this pharma stalwart is staring down a steep patent cliff and facing generic competition for its top-selling drug. Will Merck crumble under its own weight, or will it continue to pay dividends to investors for another century? To find out if this pharma giant has the stamina to keep its Bunsen burners alight, grab your copy of our brand-new premium research report today. Our senior biotech analyst Brian Orelli, Ph.D., walks you through both the opportunities and threats facing Merck, and the report comes with a full 12 months of updates. Claim your copy now by clicking here.